Susceptibility of diverse primary HIV isolates with varying co-receptor specificity's to CXCR4 antagonistic compounds.

@article{Owen2002SusceptibilityOD,
  title={Susceptibility of diverse primary HIV isolates with varying co-receptor specificity's to CXCR4 antagonistic compounds.},
  author={Sherry Michele Owen and Donna Rudolph and Dominique Schols and Nobutaka Fujii and Naoki Yamamoto and Renu B. Lal},
  journal={Journal of medical virology},
  year={2002},
  volume={68 2},
  pages={
          147-55
        }
}
The chemokine receptors CCR5 and CXCR4 are an obvious target for HIV therapies. Two compounds, T-22 and AMD-3100, have been shown to inhibit infection of CXCR4-using HIV-1 isolates. The specificity of T-22 and AMD-3100 was further confirmed by their ability to block entry of HIV-1 in GHOST-CXCR4 transfected cells with no effect on viral entry in the GHOST-CCR5 cells. The ability of T-22 to block replication of diverse HIV-1 isolates (group M, subtypes A, B, D, E, and F as well as group O) and… CONTINUE READING